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Marfan’s syndrome is a genetic disorder affecting connective tissues, and it can lead to death due to aortic
defects if left untreated. b-blocker therapy has been used to slow the progression of this disease. Brooke
et al. now report in this issue of Developmental Cell that combining angiotensin II receptor blockade by
losartan with b-blocker treatment is an effective treatment combination therapy for this disorder.Marfan’s syndrome is an autosomal dom-
inant systemic connective tissue disorder
caused by mutations in the extracellular
matrix (ECM) protein fibrillin-1 (Judge
and Dietz, 2005). Cardiovascular, skele-
tal, and ocular systems are frequently
involved along with mortality associated
with proximal aortic aneurysm (dilation)
and dissection (tearing of the wall) in as
many as 40% of patients if left untreated.
Four decades ago, Hugh Bentall intro-
duced composite graft aortic root re-
placement in Marfan patients, offering
the possibility of a normal life span.
It has long been thought that aortic root
aneurysm in Marfan’s syndrome is
caused by deficiency in fibrillin, resulting
in fragmentation of elastin and a weak-
ened aorta, which is prone to rupture. b-
blocker therapy has been the mainstay
of medical treatment based on the hemo-
dynamic consideration of reducing the
rate of pressure change in the aortic root
(Shores et al., 1994). However, rodent
studies have indicated that angiotensin II
receptor blockade therapy was more ef-
fective than b-blocker therapy in treating
fibrillin-deficient mice with aneurysms
(Habashi et al., 2006). Now, in an article
in the New England Journal of Medicine,
Brooke et al. (2008) present the first report
where angiotensin II receptor blockade
halts the progression of aortic root dilation
in human children (aged 1 to 16 years), of-
fering the promise of an additional medi-
cal therapy with significant effectiveness.
This exciting study constitutes direct
clinical application of recent basic re-
search on the molecular mechanism ofthe disease. Recent studies recognized
that ECM proteins play a crucial role in
the regulation of cytokine bioavailability
in the vascular system—in particular, the
release of vascular endothelial growth
factor (VEGF) and latent transforming
growth factor b (TGF-b) (Kalluri, 2003;
ten Dijke and Arthur, 2007). The TGF-b
family of proteins is composed of over
30 secreted cytokines in mammals, in-
cluding three TGF-b isoforms, activins,
and bone morphogenetic proteins, signal-
ing through five type II receptors and
seven type I receptors. The TGF-b family
of proteins is involved in development as
early as primitive streak formation, and
plays an important role during hematopoi-
esis and organogenesis of the heart, kid-
ney, bone, liver, GI tract, and vasculature.
TGF-b family members continue to main-
tain tissue homeostasis in the adult, func-
tioning through the autocrine, paracrine,
and sometimes endocrine systems. Their
dysregulation has been implicated in
many human diseases such as cancer,
fibrosis, autoimmune disease, and vascu-
lar disease (Zeisberg et al., 2003; ten Dijke
and Arthur, 2007).
TGF-b isoforms are all synthesized as
precursor proteins and mostly secreted
as large latent complexes (LLCs). The
LLCs are composed of large latent TGF-
b-binding proteins (LTBP) covalently at-
tached to the small latent complexes that
are formed by latency-associated peptide
noncovalently linked to the dimerized
TGF-b (ten Dijke and Arthur, 2007). LTBP
contains multiple epidermal-growth-fac-
tor-like repeats, which are also present inDevelopmefibrillin-1. After secretion, the LLC binds
to the ECM via binding of LTBP to fibrillin,
which is required for effective TGF-b acti-
vation. TGF-b signaling requires release of
the mature TGF-b embedded in the ECM
and basement membranes by proteases
or matrix metalloproteases in a tightly
controlled manner to allow interaction
with its receptor complexes, and initiation
of downstream signaling cascades (ten
Dijke and Arthur, 2007). A reduced amount
of fibrillin-1 may result in deficiency of LLC
sequestration and excessive activation
of TGF-b signaling, as demonstrated in
mice with deficiency of fibrillin-1, which
exhibit features of Marfan’s phenotype
(Neptune et al., 2003). The aortic aneu-
rysm in these mice can be prevented by
either prenatal or postnatal administration
of TGF-b neutralizing antibodies.
The angiotensin pathway provides an-
other way to target TGF-b. Angiotensin II
is a potent vasoconstrictor that signals
through the angiotensin II type I (AT1)
receptor and has long been known to
upregulate TGF-b1 in animal experiments
(Everett et al., 1994). In addition, angioten-
sin II activates thrombospondin-1 (Zhou
et al., 2006), which is a potent activator
of TGF-b signaling. Angiotensin II also sig-
nals through angiotensin II type II receptor,
which antagonizes AT1 signaling.
Agents that can block the angiotensin
receptor, such as losartan (an AT1 recep-
tor antagonist; see Figure 1), were initially
developed to reduce blood pressure. In
the years since their introduction into
the clinic, numerous studies have con-
vincingly established the molecularntal Cell 15, July 2008 ª2008 Elsevier Inc. 1
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and TGF-b-induced matrix production.
Subsequent studies demonstrated the
efficacy of losartan in decreasing TGF-b
signaling. The study by Brooke and col-
leagues extends this research to evaluate
the efficacy of losartan in targeting TGF-b
activity via ECM manipulation in children
with Marfan’s syndrome.
Brooke et al. report that children on
b-blocker therapy alone showed a mean
aortic root diameter increase of 3.54 ±
2.87 mm/year as compared with 0.46 ±
0.62 mm/year in children receiving a com-
bination of losartan and b-blocker ther-
apy. This trend continued over several
years during which the children were
followed. Thus, losartan was effective in
counteracting the increase in TGF-b sig-
naling in Marfan patients. This study high-
lights the importance of cytokine activa-
tion by ECM manipulation and opens up
exciting treatment possibilities for other
conditions in which TGF-b is abnormally
expressed, such as Duchenne muscular
dystrophy, organ fibrosis, cancer pro-
gression, and many others.
The study of rare genetic diseases often
leads to a better molecular understanding
and novel treatments of more common
diseases. Aortic aneurysm and dissection
is the fifteenth leading cause of death in
the U.S. and accounts for 0.7% of total
deaths. The usual risk factors include
smoking, male gender, atherosclerosis,
and hypertension. b-blockers have been
the only treatment modality, in combina-
tion with reducing underlying risk factors.
In a recent report using a mouse model of
thoracic aortic aneurysm, TGF-b signaling
alterations were convincingly demon-
strated. Perhaps inhibition of TGF-b sig-
naling may prove to be fruitful in treating
these patients.
While the prospect of targeting TGF-b
signaling may lead to future therapies
Figure 1. Magnetic Resonance Images of a Normal and a Marfan’s Dilated Aortic Root
Brooke et al. (2008) suggest that specific AT1 inhibition by losartan blocks TGF-b signaling, preventing del-
eterious effects that ultimately result in aortic root dilation. The magnetic resonance images were provided
by the BIDMC Division of Cardiology.2 Developmental Cell 15, July 2008 ª2008 Elsevier Inc.against many diseases, we must also rec-
ognize that normal TGF-b signaling is crit-
ical for development, adult tissue homeo-
stasis, and immune function. In particular
we must be cautious when considering
TGF-b-related therapies in children.
Brooke et al. found a drop in the linear
growth of body height in treated children.
Therefore, losartan may not be a viable
long-term treatment option for very young
children. The authors report insignificant
change in renal function after 3 months
of therapy, but the deleterious effect of
AT1 inhibition on renal development is
well-established in rodents. The balance
between the need for TGF-b in normal de-
velopment and suppression of its activity
in the treatment of disease must be care-
fully considered and evaluated. Future
work should focus on identifying novel
ways to target TGF-b specifically at the
arterial wall interface.
REFERENCES
Brooke, B.S., Habashi, J.P., Judge, D.P., Patel, N.,
Loeys, B., and Dietz, H.C. (2008). N. Engl. J. Med.
358, 2787–2795.
Everett, A.D., Tufro-McReddie, A., Fisher, A., and
Gomez, R.A. (1994). Hypertension 23, 587–592.
Habashi, J.P., Judge, D.P., Holm, T.M., Cohn,
R.D., Loeys, B.L., Cooper, T.K., Myers, L., Klein,
E.C., Liu, G., Calvi, C., et al. (2006). Science 312,
117–121.
Judge, D.P., and Dietz, H.C. (2005). Lancet 366,
1965–1976.
Kalluri, R. (2003). Nat. Rev. Cancer 3, 422–433.
Neptune, E.R., Frischmeyer, P.A., Arking, D.E.,
Myers, L., Bunton, T.E., Gayraud, B., Ramirez, F.,
Sakai, L.Y., and Dietz, H.C. (2003). Nat. Genet.
33, 407–411.
Shores, J., Berger, K.R., Murphy, E.A., and Pyeritz,
R.E. (1994). N. Engl. J. Med. 330, 1335–1341.
ten Dijke, P., and Arthur, H.M. (2007). Nat. Rev.
Mol. Cell Biol. 8, 857–869.
Zeisberg, M., Hanai, J., Sugimoto, H., Mammoto,
T., Charytan, D., Strutz, F., and Kalluri, R. (2003).
Nat. Med. 9, 964–968.
Zhou, Y., Poczatek, M.H., Berecek, K.H., and Mur-
phy-Ullrich, J.E. (2006). Biochem. Biophys. Res.
Commun. 339, 633–641.
